Vendor Intelligence Report: Limitless Life Nootropics

Published 13 Jun 2026. 25-page investigative report on who is behind Limitless Life Nootropics: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 22 Finnrick lab tests, Limitless Life Nootropics records 7 passes against 15 failures, a 32% overall pass rate. The lab record is product-specific and sharply uneven. BPC-157 is the relative bright spot if a buyer is constrained to this vendor, Retatrutide is more mixed than its headline rating suggests, and CJC-1295 is the clearest avoid signal; a second fail-heavy peptide is resolved in the full breakdown. The stricter-grading view matters because ratings become less forgiving under tighter purity and fill thresholds.

Off-lab findings sharpen the caution. Florida filings tie the operation to an active Live Limitless LLC, an inactive related holding company, and named principals across the Limitless Life Nootropics to Limitless Biotech transition. Archived pages support real pre-2019 history, but jail records captured during the investigation show the founder/managing member in a no-bond custody posture after multiple bookings.

An Ohio pharmacy-board record also puts the rebrand in a regulated dangerous-drug fact pattern, naming Limitless Biotech as an unlicensed Florida source of DSIP for a clinic. The COA trail is just as important: records point to Qi'an/Xi'an Genotide, a Chinese peptide manufacturer/supplier, appearing where buyers would expect independent third-party testing, leaving USA-made and GMP-style claims unverified.

The marketing channel is noisy. The report maps a broad discount-code ecosystem, including practitioner and influencer endorsements, with many referral-bearing posts lacking clear disclosure in the captured evidence. Complaint and payment records add a practical warning: preserve chargeback rights and do not treat affiliate praise as batch evidence.

Inside the full report:

  • Per-product Finnrick breakdown and methodology-divergence charts for all 4 tested peptides
  • Florida Sunbiz records for the active operating LLC and inactive holding company
  • Wayback archive, Certificate Transparency, and rebrand exhibits linking both brand names
  • Santa Rosa County jail-record timeline and leadership-continuity analysis
  • Ohio pharmacy-board DSIP citation and Qi'an/Xi'an Genotide COA integrity review
  • Affiliate-code scan, complaint themes, and Cash App/Zelle/crypto recourse analysis

Risk assessment

  • Leadership-continuity risk — high: Santa Rosa County jail records captured June 2026 showed founder/managing member Christopher Michael Mercer held with no bond after four bookings in eight months.
  • Regulatory-enforcement risk — high: Ohio Board of Pharmacy Case A-2025-0306 named Limitless Biotech as an unlicensed Florida supplier of DSIP to a clinic administering dangerous drugs.
  • COA / third-party-testing integrity risk — high: Records indicate LLN COAs listed Qi’an/Xi’an Genotide, a Chinese peptide manufacturer/supplier, rather than an independent analytical laboratory.
  • Product-quality risk — CJC-1295 and Ipamorelin — high: Finnrick shows CJC-1295 at 0/8 pass (15.42%) and Ipamorelin at 0/4 pass (55.62%); these are poor choices from this vendor.
  • Product-quality risk — Retatrutide — medium: Retatrutide has the vendor’s strongest current rating (75.93%) but a split 2/4 pass record, so treat it as mixed rather than settled.
  • Affiliate-promotion and disclosure risk — medium: Affiliate scan found 25 promoters; 23 carried referral code/link and 19 lacked clear disclosure, including quality claims tied to codes.
  • Payment / chargeback-protection risk — medium: BBB complaint records documented Cash App payments to Angela totaling $828.72 and field review recorded a 10% credit-card surcharge.